Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.60 |
| ▸ | MMP9 | P14780 | 10/20 | 0.54 |
| ▸ | MMP2 | P08253 | 8/20 | 0.54 |
| ▸ | MMP14 | P50281 | 3/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514383 | 0.94 | PTGS2 (0.65) | PTGS2MMP9MMP2MMP14KIF11 | |
| SCHEMBL7673984 | 0.89 | PTGS2 (0.68) | PTGS2KIF11FFAR4BCHEACHE | |
| SCHEMBL8941548 | 0.87 | PTGS2 (0.50) | PTGS2MMP9MMP2MMP14FFAR4 | |
| SCHEMBL9779140 | 0.85 | MMP9 (0.56) | MMP9MMP2MMP14FFAR4SLC6A4 | |
| SCHEMBL11547843 | 0.84 | HTT (0.58) | PTGS2 | |
| SCHEMBL10949316 | 0.82 | PTGS2 (0.44) | PTGS2MMP9MMP2MMP14SLC6A4 | |
| SCHEMBL7990329 | 0.81 | PTGS2 (0.57) | PTGS2MMP9MMP2MMP14KIF11 | |
| SCHEMBL5482429 | 0.81 | MMP9 (0.54) | MMP9MMP2MMP14NR3C1MMP1 | |
| SCHEMBL3310741 | 0.81 | MMP9 (0.54) | MMP9MMP2MMP14FFAR4SLC6A4 | |
| SCHEMBL28780452 | 0.79 | EPHX2 (0.50) | MMP9MMP2MMP14KIF11SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003063762-A2 | PROCESS FOR THE PREPARATION OF MATRIX METALLOPROTEINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-08-07 | — | — | WO | claimed |
| WO-2003063762-A2 | PROCESS FOR THE PREPARATION OF MATRIX METALLOPROTEINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-1274586-A2 | PREPARATION OF LIGHT-EMITTING, HIGHLY REFLECTIVE AND/OR METALLIC-LOOKING IMAGES ON A SUBSTRATE SURFACE | SRI INTERNATIONAL (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1147101-B1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020128496-A1 | Process for the preparation of matrix metalloproteinase inhibitors | ABBOTT LABORATORIES | 2002-09-12 | — | — | US | disclosed |
| US-6350902-B2 | REACTING HYDROXYAMINE WITH A TRIFLUOROFORMATE ESTER | ABBOTT LABORATORIES | 2002-02-26 | — | — | US | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-20020002307-A1 | Process for the selective N-formylation of N-hydroxylamines | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| EP-1147101-A1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2001-10-24 | — | — | EP | disclosed |
| US-20010031896-A1 | Process for the selective N-formylation of N-hydroxylamines | ABBOTT LABORATORIES | 2001-10-18 | — | — | US | disclosed |
| WO-2001070508-A2 | PREPARATION OF LIGHT-EMITTING, HIGHLY REFLECTIVE AND/OR METALLIC-LOOKING IMAGES ON A SUBSTRATE SURFACE | SRI INTERNATIONAL (US) | 2001-09-27 | — | — | WO | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| WO-2000044739-A1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044712-A1 | N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031896-A1 | Process for the selective N-formylation of N-hydroxylamines | HNMT, INMT, PNMT | PTGS2 1251/4885MMP9 2786/4885MMP2 3410/4885 |
| US-20020002307-A1 | Process for the selective N-formylation of N-hydroxylamines | HNMT, INMT, PNMT | PTGS2 1251/4885MMP9 2786/4885MMP2 3410/4885 |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | PTGS2 199/4885MMP9 2/4885MMP2 4/4885 |
| US-20020128496-A1 | Process for the preparation of matrix metalloproteinase inhibitors | MMP9, MMP2, MMP14 | PTGS2 188/4885MMP9 1/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.